## STATEMENT OF CAPITAL STRUCTURE

The capital structure of NeuroScientific Biopharmaceuticals Ltd (ACN 102 832 995) (**Company**) as at the date of quotation is set out below.

| | |
|---|---|
| **Shares [1]** | 73,580,592 |
| **Options[2]** | 36,000,000 |
| **Performance Shares[3]** | 2,800,000 |

**Notes:**

1.  The rights attaching to the Shares are summarised in the prospectus in section 13.2 of the prospectus dated 9 May 2018 (**Prospectus**).
2.  The Options are exercisable at $0.20 on or before 7 March 2021. The full terms and conditions attaching to the Options are set out in section 13.5 of the Prospectus.
3.  The Company has issued 2,800,000 Performance Shares comprising of 700,000 Class B Performance Shares, 700,000 Class C Performance Shares, 700,000 Class D Performance Shares and 700,000 Class E Performance Shares. The rights attaching to the Performance Shares are summarised in section 13.3 of the Prospectus.

## RESTRICTED SECURITIES

The Company confirms that following admission to quotation of the Company's securities on the ASX, the following securities will be restricted pursuant to the ASX Listing Rules for the period outlined below.

| Securities | Restriction Period |
|---|---|
| 19,349,506 Ordinary Fully Paid Shares | 24 months from date of quotation |
| 36,000,000 Options[1] | 24 months from date of quotation |
| 2,800,000 Performance Shares[2] | 24 months from date of quotation |
| 1,160,000 Ordinary Fully Paid Shares | 12 months from the date of issue, being 24 July 2018 |
| 746,269 Ordinary Fully Paid Shares[3] | 12 months from the date of issue, being 18 January 2018 |

**Notes:**

1.  Options exercisable at $0.20 on or before 7 March 2021. The full terms of the Options are set out in section 13.5 of the Prospectus.
2.  The Company has issued 2,800,000 Performance Shares comprising of 700,000 Class B Performance Shares, 700,000 Class C Performance Shares, 700,000 Class D Performance Shares and 700,000 Class E Performance Shares. The rights attaching to the Performance Shares are summarised in section 13.3 of the Prospectus.